Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer’s acquisition offer, the company said. Alexza noted that the letter of intent allows the company to continue to explore other options, and there is no guarantee that it will complete the deal with Ferrer.
In September 2015, Alexza announced that it was exploring various strategic options. In December of that year, the company said that it would reacquire US rights to Adasuve inhaled loxapine from Teva. Grupo Ferrer markets Adasuve in most of the other countries where it is approved.
Read the Alexza Pharmaceuticals press release.
